A candid, harm-reduction look at cardarine, its endurance and fat-oxidation effects, and the rodent carcinogenicity signal that ended its development.
At a glance
Cardarine, developed as GW-501516, is a PPAR-delta agonist. It is often grouped with SARMs and sold alongside them, but it is not a SARM and does not act on the androgen receptor. It shifts metabolism toward fat oxidation and is used for endurance and fat loss.
The most important fact about cardarine comes first: GlaxoSmithKline halted its development in 2007 after a long-term rodent carcinogenicity study showed tumors developing in multiple organ systems, including liver, stomach, skin, and bladder, at high doses. This guide is written as harm-reduction tracking for people who have already decided to use it, not as a recommendation, and it is not medical advice.
The defining concern is the rodent carcinogenicity that ended clinical development; no long-term human safety data exists because the trials never got that far. Anyone using it is accepting an unquantified cancer risk. It is also an unregulated research chemical, so mislabeling and contamination add further uncertainty. The honest harm-reduction position is to keep any exposure minimal, brief, and fully informed.
Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.